Raymond James Financial Inc. Acquires New Shares in InflaRx (NASDAQ:IFRX)

Raymond James Financial Inc. bought a new position in InflaRx (NASDAQ:IFRX - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 638,092 shares of the company's stock, valued at approximately $1,576,000. Raymond James Financial Inc. owned approximately 1.08% of InflaRx at the end of the most recent quarter.

Separately, Commonwealth Equity Services LLC grew its position in InflaRx by 20.5% in the fourth quarter. Commonwealth Equity Services LLC now owns 111,500 shares of the company's stock valued at $275,000 after acquiring an additional 19,000 shares during the period. 42.39% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on IFRX shares. Oppenheimer assumed coverage on shares of InflaRx in a research note on Thursday. They issued an "outperform" rating and a $6.00 target price on the stock. Cantor Fitzgerald initiated coverage on shares of InflaRx in a research note on Tuesday, April 29th. They set an "overweight" rating and a $10.00 price objective on the stock. HC Wainwright restated a "buy" rating and set a $8.00 price target on shares of InflaRx in a research report on Friday, March 21st. Finally, Guggenheim raised their price objective on shares of InflaRx from $7.00 to $10.00 and gave the company a "buy" rating in a research report on Wednesday, March 26th.

InflaRx Stock Performance

IFRX traded down $0.01 during trading on Thursday, reaching $1.48. 26,662 shares of the company's stock were exchanged, compared to its average volume of 357,249. The company's fifty day moving average price is $1.21 and its 200-day moving average price is $1.82. The firm has a market capitalization of $99.36 million, a PE ratio of -1.37 and a beta of 1.57. InflaRx has a fifty-two week low of $0.82 and a fifty-two week high of $2.82.

InflaRx (NASDAQ:IFRX - Get Free Report) last released its quarterly earnings data on Thursday, March 20th. The company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.27) by $0.18. InflaRx had a negative return on equity of 65.98% and a negative net margin of 33,362.70%. Research analysts forecast that InflaRx will post -1.04 earnings per share for the current fiscal year.

InflaRx Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.